Purpose of review Anemia is prevalent in patients with infections and other inflammatory conditions. Induction of the iron regulatory hormone hepcidin has been implicated in the pathogenesis of anemia of inflammation. This review outlines recent discoveries in understanding how hepcidin and its receptor ferroportin are regulated, how they contribute to anemia of inflammation, and how this knowledge may help guide new diagnostic and therapeutic strategies for this disease.
INTRODUCTION
Anemia is a common complication in patients with infections, autoimmune disorders, malignancy, chronic kidney disease, and other inflammatory disorders. This disorder has been termed anemia of inflammation or anemia of chronic disease, and is the second most common form of anemia worldwide [1 & ,2]. A similar condition is seen in the elderly, although often in the absence of a specific underlying disease [3] . Typically, anemia of inflammation is normocytic, normochromic, and mild to moderately severe. A hallmark of anemia of inflammation is decreased availability of circulating iron for erythropoiesis despite adequate body iron stores.
PATHOGENESIS OF ANEMIA OF INFLAMMATION
The cause of anemia of inflammation is multifactorial, and the pathophysiologic mechanisms are still being defined [1 & ,2]. Erythrocyte survival is shortened, in part because of macrophage activation by inflammatory cytokines, although hemolysis may also contribute. Inflammatory cytokines impair erythropoiesis by inhibiting the production and function of erythropoietin, and by directly inhibiting erythroid progenitor cell proliferation and differentiation. Importantly, inflammation also induces the iron regulatory hormone hepcidin and suppresses the iron exporter ferroportin to restrict the supply of iron for erythropoiesis.
aged erythrocytes by macrophages, and release from hepatocyte stores. Ferroportin is the sole known mammalian exporter responsible for iron entry into the bloodstream from these sources. Ferroportin is regulated by hepcidin, a 25-amino-acid peptide hormone secreted by the liver (Fig. 1) . Upon binding to hepcidin, ferroportin is ubiquitinated on key lysine residues, endocytosed, and degraded in lysozomes, thereby inhibiting iron entry into the bloodstream. The crystal structure of a putative bacterial homologue of ferroportin was recently solved, which may yield important new insights into how ferroportin transports iron, and how hepcidin interacts with ferroportin to regulate its activity [6 && ]. Ferroportin also undergoes additional transcriptional and posttranscriptional regulation in a cell-type specific manner [5 & ].
HEPCIDIN REGULATION
As a key regulator of systemic iron balance, hepcidin transcription in the liver is controlled by a complex interplay of signals, most notably inflammation, iron status, and erythropoietic drive [4,7 && ]. Circulating and tissue iron upregulate hepcidin to limit further iron entry, whereas erythropoietic drive suppresses hepcidin to increase iron availability for erythrocyte production. Hepcidin induction by inflammation is presumed to have evolved to sequester iron from pathogenic microorganisms.
Hepcidin regulation by iron and the bone morphogenetic protein/SMAD pathway
At the molecular level, the bone morphogenetic protein 6 (BMP6)-SMAD1/5/8 pathway is a central transcriptional regulator of hepcidin in response to iron [8] (Fig. 1) How iron levels are sensed to regulate BMP-SMAD1/5/8 signaling and hepcidin are areas of active investigation [8] . Increases in liver iron induce BMP6 expression, predominantly in liver nonparenchymal cells, while circulating iron induces SMAD1/5/8 phosphorylation downstream or independent of BMP6. Transferrin receptors 1 and 2 likely function as sensors of circulating iron, and interact with the hemochromatosis protein HFE to regulate BMP-SMAD1/5/8 signaling and hepcidin. The transmembrane serine protease 6 was demonstrated to cleave hemojuvelin, and functions as a negative regulator of this pathway in response to iron deficiency. Neogenin is a hemojuvelin interacting protein that may also participate in hepcidin regulation. Although recent studies propose some models for how these pathways and proteins may interact [10, 11] , the precise molecular mechanisms remain incompletely understood (Fig. 1) .
Hepcidin regulation by inflammation
Inflammatory cytokines, in particular IL-6, regulate hepcidin transcription via the Janus kinase-signal transducer and activator of transcription 3 pathway [7 && ] (Fig. 1) . Recent studies confirm an important role for IL-6 in hepcidin induction by many different infections, including Streptococcus pneumonia and
KEY POINTS
Anemia of inflammation has a complex pathophysiology depending on the underlying disease process, but major contributing factors include reduced iron availability, impaired erythrocyte production, and shortened erythrocyte survival.
The hypoferremia of anemia of inflammation is largely mediated by hepcidin, which acts to degrade ferroportin and inhibit iron entry into plasma, although some hepcidin-independent mechanisms may also have a role.
IL-6 is a key inducer of hepcidin in most models of anemia of inflammation by promoting phosphorylation of STAT3, which acts together with SMAD1/5/8 to activate the hepcidin promoter.
Low hepcidin levels may help distinguish patients with IDA versus anemia of inflammation, and patients who may benefit most from iron or ESAs in certain populations, but more work is needed to understand the clinical utility of hepcidin assays.
Numerous inhibitors of hepcidin production or action have shown promise to treat anemia of inflammation in preclinical studies, and are now entering human clinical trials.
influenza A, as well as most extracellular pathogenassociated molecular patterns, as IL-6 knockout mice demonstrated impaired or absent hepcidin induction to these stimuli [12 & ]. However, IL-22, which can induce hepcidin expression both in vitro and in vivo, has only a minor role in hepcidin induction by lipopolysaccharide (LPS) as demonstrated by studies in IL-22 knockout mice [13] . A role for IL-22 in other infectious or inflammatory conditions in vivo remains to be determined. IL-1 can also regulate hepcidin, either by inducing IL-6 or by IL-6-independent mechanisms [14, 15] . A recent study confirmed that IL-1b stimulates hepcidin and induces hypoferremia in mice, and proposed an alternate mechanism through the induction of SMAD1/5/8 signaling [16] . This pathway was implicated as a mechanism for hepcidin induction by commensal intestinal bacteria with potential relevance to inflammatory bowel disease, although the relevance in vivo remains to be established [16] .
Crosstalk between inflammation and the SMAD1/5/8 pathway in hepcidin regulation ], whereas they showed some improvement in iron overload and ineffective erythropoiesis in a b-thalassemia model [28] . Notably, erythroferrone knockout mice also had higher hepcidin, more pronounced iron restriction, and more severe anemia in a heat-killed Brucella abortus mouse model of anemia of inflammation, suggesting that erythroferrone may assist in the recovery from anemia of inflammation [27] . Based on the erythroferrone knockout mouse phenotype, there are likely additional unidentified erythroid regulators of hepcidin.
HEPCIDIN AND THE PATHOGENESIS OF ANEMIA OF INFLAMMATION
Recent studies explored the contribution of hepcidin versus other factors to the pathogenesis of anemia of inflammation, and how this varies in different underlying diseases.
Disease-specific effects
In B. abortus and turpentine mouse models, hepcidin knockout mice exhibited less severe anemia and a lack of iron restriction compared with wild-type mice, confirming an important functional role for hepcidin in anemia of inflammation, at least in these models [29 && ,30,31]. However, hepcidin knockout mice still exhibited some anemia of inflammation features, including reduced erythroid progenitor cells, erythropoiesis, and red blood cell number. IL-6 knockout mice were also partially protected against anemia of inflammation in the Brucella abortus model, and exhibited faster recovery of erythropoiesis, suggesting a distinct role for IL-6 in anemia of inflammation pathophysiology by suppressing erythropoiesis [29 && ]. Recently, IL-6 was demonstrated to reduce mitochondrial membrane potential in an erythroleukemic cell line to impair hemoglobin production and erythroid maturation, suggesting at least one mechanism for IL-6 to inhibit erythropoiesis [32] . Although these animal models have some limitations, they are valuable tools to dissect the pathophysiology of anemia of inflammation and test new therapeutic strategies.
In a mouse model of anemia of aging [3], older mice exhibited reduced hemoglobin, reduced erythrocyte numbers, increased myeloid lineage cells, and increased IL-6 and IFNg. Although hepcidin was not higher, it may have been inappropriately high relative to the degree of anemia. Aged IL-6 and hepcidin knockout mice each exhibited less severe anemia, suggesting that both contribute to the anemia of aging, but other factors also contribute, potentially IFNg and other modifiers of erythroid and myeloid progenitor commitment.
The cause of anemia of cancer was also recently examined. In a prospective observational cohort of patients with solid tumors before receiving treatment [33], hemoglobin was inversely associated with inflammatory markers, hepcidin, ferritin, erythropoietin, reactive oxygen species, cancer stage, and performance status, whereas it was positively correlated with serum iron, transferrin, and nutritional markers, including albumin and leptin. By multivariate analysis, IL-6, leptin, and cancer stage were independent predictors of hemoglobin. Differences were seen with different cancer types, with colorectal cancer exhibiting low hepcidin, serum iron, and ferritin, suggesting a component of iron deficiency anemia (IDA). In four mouse models of anemia of cancer [34] , most models exhibited inflammation and iron-restricted erythropoiesis, but only one model had elevated hepcidin. An ovarian cancer model exhibited features of IDA without inflammation. Notably, anemia was not ameliorated by hepcidin knockout, suggesting that anemia is predominantly hepcidin-independent in these cancer models. Together, these data highlight the multifactorial nature of anemia of cancer related to inflammation as well as nutritional and metabolic components, and underscore important differences among cancer types.
Pathogen-specific effects
Pathogenic microorganisms require iron for growth and survival and have evolved sophisticated mechanisms for acquiring host iron. Humans and other hosts have similarly evolved to restrict iron from invading pathogens. Recent evidence for this evolutionary struggle comes from analysis of transferrin, which chaperones iron in the bloodstream, and transferrin-binding protein A (TbpA), a bacterial protein which hijacks transferrin to procure iron [35 && ]. The authors identified several hotspots on transferrin and TbpA that have undergone rapid coevolution, with transferrin variants selected to preclude TbpA binding, and TbpA mutations counter selected to recapture the modified transferrin. Hepcidin induction by inflammation is presumed to have evolved as another mechanism of nutritional immunity to sequester iron from invading pathogens and possibly also modify the immune response. However, direct experimental evidence for this host defense function of hepcidin and hypoferremia is only starting to emerge.
One developing theme is that hepcidin-ferroportin modulation may be different, and the effects may be beneficial or harmful depending on the pathogen and its niche. For example, while many infections upregulate hepcidin and induce hypoferremia, hepatits B and hepatitis C viruses do not elicit a systemic inflammatory response or induce hepcidin or hypoferremia [36] .
A protective role for hepcidin and hypoferremia is most clearly established for siderophilic bacteria, acute infection caused by Salmonella Typhi or Salmonella Typhimurium was associated with significantly increased hepcidin and hypoferremia. In the mouse model, hepcidin induction was IL-6 dependent, as hepcidin and serum iron were unchanged in IL-6 knockout mice, and notably, bacterial burden was reduced. These authors identified a novel mechanism by which IL-6 regulates hepcidin transcription via estrogen-related receptor (ERRg). Notably, an inverse agonist of ERRg reduced hepcidin, normalized hypoferremia, reduced bacterial burden, and improved survival, suggesting that hepcidin-induced macrophage iron sequestration could have deleterious host effects in this model. Previous studies in this model also revealed local mechanisms in macrophages that limit iron availability, including induction of ferroportin transcription by IFNg, nitric oxide, and nuclear factor erythroid 2-related factor 2 [40] . This may help explain the reduced spleen iron levels seen in more chronic Salmonella Typhimurium infection [41] . More work is needed to better understand the diverse roles of hepcidin and iron in infection and immunity, and the reader is referred to recent reviews for more in-depth discussions [7 && ,40].
Hepcidin-independent ferroportin regulation and hypoferremia in anemia of inflammation
In addition to hepcidin-mediated ferroportin degradation, recent studies demonstrated a functional role for hepcidin-independent ferroportin transcriptional downregulation in the acute hypoferremia induced by toll-like receptor (TLR) 2/6 ligands [42 & ] and TLR4 ligands in mice [43] . Inflammatory cytokines also exert a number of other hepcidin-independent effects on iron homeostasis at multiple levels, including increasing macrophage iron uptake, increasing erythrophagocytosis, and promoting efficient iron storage [ 
HEPCIDIN-BASED DIAGNOSTIC STRATEGIES AND IMPLICATIONS FOR GUIDING THERAPY
Anemia of inflammation is diagnosed by the findings of anemia with reduced circulating iron levels despite adequate or elevated body iron stores. Serum ferritin is typically used to assess body iron stores; however, it has limited specificity because it is regulated not only by iron, but also by inflammation and numerous other factors. A particular difficulty is distinguishing isolated anemia of inflammation from IDA and mixed anemia of inflammation with IDA that might benefit from iron therapy [1 & ,2,44]. In the developing world, where IDA remains a significant global health problem that contributes to poor pregnancy outcome, impaired physical and cognitive development, and reduced work productivity, it is particularly important to identify subpopulations that may benefit from iron without increasing susceptibility to malaria and other infections as was demonstrated in some supplementation initiatives [45] . Erythropoiesis-stimulating agents (ESAs) are another therapeutic option with clear benefits for improving quality of life and reducing transfusions in chronic kidney disease patients. However, ESAs also have significant potential adverse effects, including an increased risk of stroke and other cardiovascular events, hypertension, clotting, malignancy progression, and mortality [44] . Recent studies investigated the utility of hepcidin assays for identifying patients who may most benefit from iron or ESA treatment.
In a study of African children [46 && ], serum hepcidin identified IDA and distinguished this from anemia of inflammation with an AUC ROC of 0.84-0.88. Serum hepcidin also predicted responsiveness to oral iron therapy with an AUC ROC of 0.90. In these respects, hepcidin was statistically similar or outperformed other established measures. The use of hepcidin would have allowed most children with IDA to be identified and treated, while reducing the percentage of patients with malaria and anemia of inflammation being treated from 73 and 100% to 20 and 14%, respectively. Another study in African children demonstrated that hepcidin levels were lower and the prevalence of iron deficiency increased at the end of the malaria season, which may help guide better timing for iron supplementation strategies in this patient population [47] .
In a study of 38 patients with chronic rheumatic diseases, the strongest association with hemoglobin response to iron therapy was the 1-week increase of reticulocyte hemoglobin content, transferrin saturation, serum iron, and reticulocyte count, with baseline hepcidin also predictive to a lesser degree [48] . In rats with anemia of inflammation because of group A streptococcal peptidoglycan polysaccharide, higher pretreatment hepcidin was associated with a poor hematologic response to ESAs [49] . More work is needed to understand where and how hepcidin or other assays may be useful in different patient populations with anemia of inflammation.
NOVEL THERAPEUTIC STRATEGIES FOR ANEMIA OF INFLAMMATION
Experimental agents targeting the hepcidin-ferroportin axis (Fig. 2) have recently been tested in preclinical and early clinical trials as new treatments for anemia of inflammation. One strategy targets hepcidin production by inhibiting IL-6-STAT3 signaling. The IL-6 receptor antibody tocilizumab reduced hepcidin and improved anemia and iron parameters in patients with rheumatoid arthritis [50, 51] . The IL-6 antibody siltuximab lowered hepcidin and improved anemia in patients with multicentric Castleman's Disease [52] . Hydrogen sulfide suppressed hepcidin and improved hypoferremia in LPS-treated mice by suppressing IL-6 production and promoting sirtuin 1-mediated deacetylation of STAT3 to inhibit its activity [53] .
A second strategy targets hepcidin production by inhibiting SMAD1/5/8 signaling. A small molecule BMP type I receptor inhibitor (LDN-193189) [49, 54, 55] and a soluble hemojuvelin fusion protein [55, 56] showed efficacy to lower hepcidin and mobilize iron in animal models of anemia of inflammation. Soluble hemojuvelin entered Phase 2 clinical trials to treat anemia in human patients with kidney disease (NCT02228655). Heparins and engineered heparins with low anticoagulant activity, which were shown to inhibit SMAD1/5/8 signaling by sequestering BMP ligands, lowered hepcidin, and improved hypoferremia and anemia in rodent anemia of inflammation models [57, 58] . The Activin B inhibitor follistatin-315 lowered hepcidin induction by LPS in mice [19] . BMP6 and hemojuvelin neutralizing antibodies reduced hepcidin and mobilized iron in normal rodents and monkeys [59, 60] .
Additional strategies target hepcidin directly using hepcidin antibodies, anticalins, spiegelmers, and antisense oligonucleotides, or target ferroportin. The hepcidin spiegelmer lexaptepid (NOX-H94) ameliorated IL-6-induced anemia in a primate model [61] and reversed LPS-induced hypoferremia in human patients [62 & ]. Phase 2 clinical trials are underway. A neutralizing hepcidin antibody ameliorated anemia in a rodent anemia of inflammation model and improved iron availability in monkeys [63] . A hepcidin anticalin (PRS-080) and antibody targeting the hepcidin-binding site on ferroportin (LY2928057) have undergone Phase I clinical trials (NCT02340572; NCT01330953).
CONCLUSION
Recent studies have enhanced our understanding of the complex pathophysiology of anemia of inflammation and the contribution of the hepcidin-ferroportin axis, which may differ depending on the underlying disease process. This knowledge is leading to the development of new targeted therapeutic strategies, and new diagnostic strategies to tailor therapy to those who may benefit most. There are many key areas for future research. We need to better understand the pathophysiology of anemia of inflammation in humans with different underlying diseases, how iron balance affects susceptibility to many common pathogens and the immune response, and how best to treat patients with anemia of inflammation by recognizing the benefits and risks of iron, ESAs, transfusions, and newer hepcidin lowering therapies in different anemia of inflammation populations.
Acknowledgements

None.
Financial support and sponsorship J.L.B. is supported in part by National Institutes of Health grant RO1-DK087727 and a Howard Goodman Award from the Massachusetts General Hospital.
Conflicts of interest J.L.B. has ownership interest in Ferrumax Pharmaceuticals Inc., which has licensed technology from the Massachusetts General Hospital based on work cited here and described in prior publications. Hepcidin knockout mice, dietary iron loading and depletion, and administration of hepcidin agonists were employed to elucidate the mechanism of increased susceptibility to the siderophilic bacteria V. vulnificus that is reported in hereditary hemochromatosis. Results suggest that hepcidin-mediated hypoferremia is an important host defense mechanism against this extracellular pathogen. 
